Merck + Co., Inc.

Leeyuan Huang

Otto D Hensens

John G MacConnell

Deborah L Zink

Shieh-Shung T Chen

Byron H Arison

Jerrold M Liesch

Janet C Onishi

Claude Dufresne

James D Bergstrom

George M Garrity

Raymond F White

Lawrence R Koupal

Yu L Kong

H Boyd Woodruff

Joseph Dunn, Jr

Sheo B Singh

Gerald F Bills

Seok H Lee

Fernando Pelaez

Sebastian Hernandez

Russell B Lingham

Anne W Dombrowski

Keith C Silverman

George A Doss

Sagrario M Del Val

Yiu-kuen T Lam

Laszlo R Treiber

Maria T Diez

George E Albers-Schonberg

Gregory D Berger

Jon D Polishook

Francis J Dumont

Carol F Wichmann

Mary N Omstead

Richard W Burg

E Tracy Jones

Hans E Huber

Magda M Gagliardi

Frank L VanMiddlesworth

Maria S Meinz

Gino M Salituro

Teresa D Matas

Robert P Borris

Rosalind G Jenkins

Sagrario Mochales

Isabel M Fernandez

Mary Nallin

Denis R Patrick

Robert A Giocobbe

Josep Guarro

M Dolores Vilella Amils

Marina Mojena Sanchez

Annie Z Zhao

Y K Lam

Livia Kelemen

A compound represented by the formula I is disclosed: ##STR1## or a pharmaceutically acceptable salt or hydrate thereof. The compound has inhibitory activity against the oncoprotein Raf. Also included are pharmaceutical compositions, methods of treating cancer, cultures of the producing fungal microorganism and methods of fermentative production of the compound.

Bis-aryl ethers, compositions containing such compounds and methods of

Cholesterol lowering compound

New cholesterol lowering compounds are formed from the photochemical treatment of zaragozic acid A.

Chemical compounds

New cholesterol lowering compounds are formed from the photochemical treatment of the zaragozic acids.

Cholesterol lowering compounds

This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents and antifungal agents. These compounds are also inhibitors of farnesyl protein transferase and farnesylation of the oncogene protein Ras and thus useful in treating cancer. This invention also relates to a process for obtaining compounds of structural formula (I).

Cholesterol-lowering agents

This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents. The compounds also exhibit antifungal activity and are inhibitors of farnesyl-protein transferase.

Cholesteral lowering agents

Described is a new process for producing the macrolide immunosuppressant, FK-506 under fermentation conditions utilizing the microorganism, Streptomyces sp., (Merck Culture Collection No. MA 6858) ATCC No. 55098. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.

Process for producing FK-506

This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthetase inhibitors and thus useful as cholesterol lowering agents.

Squalene synthetase inhibitors

Novel squalene synthetase inhibitors

Fermentation of a nutrient medium by a Hypomycetes fungus of the genus Memnoniella or Stachybotrys yields a product with a major component of structural formula I: ##STR1## which is an inositol monophosphate phosphatase inhibitor and thereby useful in the treatment of manic depression.

Drug for treating manic depression

A phenyl derivative of pepstatin A, which is much more potent than pepstatin in inhibiting renin enzyme activity and has significantly greater selectivity for renin over pepsin inhibition than does pepstatin, which is useful in treating hypertension and congestive heart failure.

Renin-inhibitory pepstatin phenyl derivatives

The compounds of Formula I are produced by the aerobic fermentation of a fungus of the genus GLIOCLADIUM, ATCC No. 20826. ##STR1## The compounds of Formula I are inhibitors of testosterone 5.alpha.-reductase and are useful in the treatment and prevention of acne, seborrhea, female hirsutism and benign prostatic hypertrophy.

Sterol inhibitors of testosterone 5.alpha.-reductase

3',6-Diisopentenyl-2',4'-dihydroxy-5,7-dimethoxyisoflavan has been isolated from Glycyrrhiza uralensis Fisch. It has been found that this compound and other related compounds are potent stimulators of benzodiazepine receptors and thereby useful as effective anxiolytic agents. Furthermore, these compounds have been found to be potent antidotes of avermectin.

3',6-diisopentenyl-2',4'-dihydroxy-5,7-dimethoxy-isoflavan and related

Growing community of inventors

Watchung, NJ, United States of America

Leeyuan Huang